Welcome to our dedicated page for THIOGENESIS THERAPEUTICS news (Ticker: TTIPF), a resource for investors and traders seeking the latest updates and insights on THIOGENESIS THERAPEUTICS stock.
Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company developing sulfur-containing and thiol-based prodrugs for serious pediatric and inherited diseases, particularly rare mitochondrial and metabolic disorders. The Thiogenesis news stream highlights how its lead candidate, TTI-0102, progresses through clinical development and regulatory interactions.
News releases from the company focus heavily on clinical milestones for TTI-0102. These include updates on its randomized, double-blind, placebo-controlled Phase 2 trial in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in Europe, interim analyses describing biomarker activity and biological proof-of-concept, and activation of additional European trial sites. Thiogenesis also reports on plans and regulatory clearances for a Phase 2a trial in Leigh syndrome spectrum in the United States, as well as preparations for a Phase 3 pivotal trial in nephropathic cystinosis and a Phase 2 or Phase 2a trial in pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Investors and observers can use the TTIPF news page to follow announcements about scientific presentations at mitochondrial disease conferences, late-breaking abstract acceptances, and participation in webinars and panel discussions organized by patient advocacy and research organizations. Corporate updates such as private placements, stock option grants, investor relations agreements, and patent developments related to asymmetric disulfide prodrugs of cysteamine are also reflected in the news flow.
By reviewing Thiogenesis Therapeutics news, readers gain insight into the timing and design of its clinical trials, the company’s focus on mitochondrial oxidative stress and thiol biology, and the regulatory guidance it receives in key jurisdictions. The news page can be revisited regularly to see how the TTIPF development pipeline and corporate strategy evolve over time based on company disclosures.
Thiogenesis Therapeutics (TSXV: TTI) has received final EMA clearance for its Clinical Trial Application (CTA) Part II to begin a Phase 2 clinical trial of TTI-0102 for MELAS treatment. The trial will be conducted in France and the Netherlands as a randomized, double-blind, placebo-controlled study over 6 months.
The study will involve 12 patients total, with 8 receiving TTI-0102 and 4 receiving placebo. An interim analysis will be conducted after 3 months to assess safety data, pharmacokinetics/pharmacodynamics, and biomarkers. The trial's efficacy endpoints include the 12-Minute Walking Test, Fatigue Severity Scale, and Quality of Life Assessment.
TTI-0102 is designed to increase intracellular antioxidant glutathione and amino acid taurine levels, which are typically deficient in MELAS patients. Currently, there are no approved drugs for MELAS treatment.
Thiogenesis Therapeutics presented updates on two clinical programs in mitochondrial disease at the UMDF Webcast. The company received acceptance of its Clinical Trial Application Part I for MELAS in Europe and submitted Part II in December 2024, planning a Phase 2 trial with 12 patients in Netherlands and France by Q1 2025.
For Leigh Syndrome (LS), following a pre-IND meeting with the FDA in November 2024, the company is filing an IND and plans to initiate a Phase 2a trial in Q1 2025. The company's lead product, TTI-0102, targets oxidative stress in both conditions. MELAS affects approximately 15,000 patients in the US and 20,000 in the EU, while LS occurs in about 1/40,000 births.
Thiogenesis Therapeutics (TSXV: TTI, OTC: TTIPF) has achieved DTC eligibility status in the U.S., enabling electronic settlement of its common shares and supporting its future U.S. listing plans. The company participated in the CEM conference in Miami for investor outreach. Additionally, Thiogenesis issued 521,800 shares at $0.50 per share from exercised Finder's Options, generating $260,900. The company reported $4.15 million in cash and cash equivalents as of September 30, 2024.
Thiogenesis Therapeutics (TSXV: TTI) announces the allowance of a core patent by the European Patent Office titled 'Methods For The Treatment of Cysteamine Sensitive Disorders' (European Patent No. 18858763.8). This patent, set to expire in September 2037, adds to the company's existing patents in the same family granted in the United States (2021) and Japan (2023). The company develops novel thiol compounds, including cysteamine precursors, targeting mitochondrial diseases and related metabolic conditions through their antioxidant and anti-inflammatory properties.